What is the role for population pharmacokinetics in hemophilia?
- 1 May 2017
- journal article
- Published by Future Science Ltd in International Journal of Pharmacokinetics
- Vol. 2 (2), 125-136
- https://doi.org/10.4155/ipk-2016-0018
Abstract
Prevention of bleeding in hemophilia requires that plasma levels of the deficient factor exceed the desired minimum target level. Large interindividual variability suggests that knowledge of individual pharmacokinetic (PK) would help to achieve this goal, simultaneously minimizing infusion frequency and the amount of concentrate used. Population PK (PopPK) allows for the incorporation of determinants of interpatient variability and eliminates the need for extensive postinfusion plasma sampling. Barriers to implementation of PopPK are the need for concentrate specific models, Bayesian calculation power, specific expertise for validation and appraisal of forecasted estimates. The Web Accessible Population Pharmacokinetic Service – Hemophilia ( www.wapps-hemo.org ), developed by an international research network of hemophilia centers will test if PK-guided dose individualization can improve patient important outcomes in hemophilia.Keywords
This publication has 79 references indexed in Scilit:
- Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFcHaemophilia, 2016
- Epidemiology of Inhibitors in HemophiliaPublished by Wiley ,2014
- Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New ChallengesSeminars in Thrombosis and Hemostasis, 2012
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)Journal of Thrombosis and Haemostasis, 2011
- The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis surveyHaemophilia, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia, 2004
- Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and HungaryHaemophilia, 2004
- The Hemophilias — From Royal Genes to Gene TherapyThe New England Journal of Medicine, 2001
- HAEMOPHILIA PROPHYLAXIS IN SWEDENActa Paediatrica, 1976